In the present study, we investigated if the relaxant effects of phosphodiesterase (PDE) III inhibitors on human vessels could be inhibited by a nitric oxide synthase blocker, L-NAME, or by a blocker of ATPsensitive potassium channels (K ATP ), glibenclamide. The experiments were performed using an isometric myograph in isolated human s.c. small arteries obtained from healthy donors. After a priming procedure consisting of exposure to high potassium (120 mmol litre
. Subsequently, cumulative concentration-response curves were constructed for the selective PDE III inhibitors amrinone, milrinone and enoximone, and for theophylline and dipyridamole, with and without the addition of L-NAME 100 mol litre (n : 7) (P : 0.05). There was no significant difference between any other group. From our data we conclude that the relaxant properties of amrinone, enoximone, theophylline and dipyridamole are not dependent on nitric oxide release or on interaction with K ATP channels. However, the effect of milrinone may be partly endothelium-dependent in human vessels in vitro. (Br. J. Anaesth. 1996; 76: 122-129)
Since the discovery of cyclic nucleotide phosphodiesterase (PDE) activity 30 yr ago, there have been major advances in knowledge on this group of enzymes [1] . Five families have been described, each composed of several isoforms with different patterns of tissue distribution, including cardiac muscle, vascular smooth muscle and platelets [2, 3] . Subsequently, selective isoenzyme inhibitors have been developed [4] . Theoretically, these agents may prove useful in a variety of clinical disorders, including heart failure, asthma, depression or dementia, or arterial thrombosis. None the less, their current use in clinical practice is still limited [5] .
Over the past decade, interest has focused on the selective inhibitors of the cardiac PDE peak III isoenzyme for the treatment of congestive heart failure, but the effects of chronic oral administration of these inotropic agents in this condition have been disappointing [6] [7] [8] . However, they continue to be used in the treatment of acute heart failure [9, 10] . One of the disadvantages of the currently available PDE III inhibitors, such as amrinone, milrinone and enoximone, is marked vasodilator activity at higher doses, with concomitant reductions in arterial pressure.
The precise mechanism of this vasodilator activity remains to be elucidated. There is little doubt that selective inhibition of a low Km cAMP PDE, documented in both human arteries and arteries of different animal species, plays a major role [11] [12] [13] [14] [15] . In addition, several PDE inhibitors have been shown to produce endothelium-dependent vasodilatation in animal studies [16] [17] [18] . Recently, there has been mounting interest in the role of the ATP-dependent potassium (KATP) channels in cardiovascular tissue. Opening of these KATP channels may result not only in vasodilatation, but also in marked cardioprotective anti-ischaemic effects [19, 20] .
In the present study, we investigated if the vasodilator effects of the PDE III inhibitors amrinone and milrinone, both bipyridines, the imidazolone derivative, enoximone, and the nonspecific PDE inhibitors, theophylline and dipyridamole, could be modulated by a nitric oxide synthase blocker, N G -nitro-L-arginine methyl ester hydrochloride (L-NAME) or by the KATP channel blocker, glibenclamide. The experiments were performed in isolated human s.c. small arteries, obtained from healthy donors.
Materials and methods

VESSEL DONORS
S.c. arteries were obtained from 11 healthy white female patients (aged 18-49 yr) undergoing reconstructive breast surgery. The study was approved by the hospital's medical Ethics Committee and all patients gave informed consent. The patients were free from cardiovascular disorders and were not receiving any chronic drug treatments, except for oral contraceptive agents. Surgery was performed under general anaesthesia with volatile anaesthetics, supplemented with fentanyl and vecuronium.
PREPARATION AND MOUNTING OF THE VESSELS
Small arteries were dissected atraumatically, immediately after removal of a skin segment with s.c. fat from the caudal segment of the patient's breast. After dissection, a 40-m diameter stainless steel wire was inserted into the lumen. The length of the vessels was determined using an OSM-4 10 /13 ocular lens (Olympus, Japan). Subsequently, the vessels (estimated length of 1-2 mm) were placed in an organ preservation solution (University of Wisconsin (UW)) [21] and stored at 4 ЊC for a maximum of 7 days. Before the experiment, the preparations were transferred to the chamber of an isometric myograph [22] . The wire was fixed at both ends to microscrews and a second wire was inserted, which was subsequently connected to a force transducer (Kistler Morse, DSG 6, Redmond, WA, USA). This enabled continuous measurement of the isometric wall tension of the vessel. Reproducible measurements could be obtained within at least 7 h.
The preparations were suspended in Tyrode's solution for 10 min at 37 ЊC. Throughout the experiment, the buffer solution was oxygenated with carbogen (95 % oxygen, 5 % carbon dioxide) to achieve a pH of 7.4. Subsequently, the ratio between passive wall tension and internal circumference was determined by a normalization procedure, as described by Mulvany and Halpern [23] . The internal circumference was adjusted to a value that equals 90 % of the circumference generated by a transmural pressure of 100 mm Hg (13.3 kPa). This value was then divided by to obtain the normalized lumen diameter. Mechanical responses were expressed as active tension, ␦T (N m 91 ), that is the developed active force divided by twice the vessel segment length.
At the beginning of each experiment, the preparations were contracted three times for 5 min with high potassium Tyrode's solution (K ; 120 mmol litre
91
, see below) and once with phenylephrine 10 mol litre
, an ␣ 1 adrenoceptor agonist, at intervals of 15 min. Between these episodes the chambers were flushed at least three times with Tyrode's solution. This episode was followed by an equilibrium period of 30 min for the L-NAME and control groups and 60 min for the glibenclamide group. L-NAME 100 mol litre 91 or glibenclamide 1 mol litre 91 was added at the beginning of this period and remained present in the bath thereafter. An equilibrium period of 60 min was chosen for glibenclamide as this drug has a slow onset of action. Subsequently, U46619, a thromboxane A 2 mimetic agent, was administered to all preparations at a concentration of 1 mol litre
. After stabilization of the contraction, a cumulative concentrationresponse curve, using concentrations of 0.1 mol litre 91 to 1 mmol litre
, was constructed for amrinone, milrinone, enoximinone, theophylline and dipyridamole.
Our experimental model included two separate force transducers connected to one single organ bath, which enabled simultaneous evaluation of the contractile responses of two vessels to one drug combination. Therefore, the experiments described were performed in duplicate if sufficient vessels could be harvested from the patient's breast. The data of these duplicate experiments were averaged and listed in the results section for each individual patient.
To evaluate the effects of the preservation technique on endothelial function, the response of contracted arteries to methacholine 10 95 mol litre 91 was determined immediately after dissection of the blood vessel and after preservation in UW fluid. These vessels were not used in any other experiment.
SOLUTIONS AND DRUGS USED
In all experiments, Tyrode's solution of the following composition was used (mmol litre
91
): NaCl 136; NaHCO3 11.9; NaH2PO4 0.42; KCl 2.5; CaCl2 1.8; MgCl2 0.5; and glucose 5.5. In the high potassium Tyrode's solution, NaCl 117.5 mmol litre 91 was replaced by KCl, resulting in a total potassium concentration of 120 mmol litre
. These solutions were prepared just before each experiment. Aliquots of 20 ml were kept at 37 ЊC and bubbled with carbogen before they were introduced into the bath.
Amrinone and milrinone (donated by Sanofi Winthrop, Dev. Centre, Fawdon, UK) and enoximone (donated by Marion Merrell Dow Inc., Cincinatti, OH, USA) were dissolved to a concentration of 10 91 mol litre
. Milrinone was dissolved in distilled H2O, amrinone and enoximone were dissolved in 99 % dimethylsulphoxide (DMSO). Subsequently, these agents were diluted to 10
92
-10
95 mol litre 91 in distilled water (amrinone and milrinone) or 66.7 % DMSO (enoximone).
Theophylline and dipyridamole (Sigma Chemical Co., USA) were dissolved in distilled water and 66.7 % DMSO, respectively, and subsequently diluted to 10 92 -10 95 mol litre 91 in distilled water. The final concentrations (:1 %) of DMSO in the bathing medium had no significant effect on vascular smooth muscle contraction and relaxation. (See fig. 1 for the chemical structures of the various compounds studied.)
Nitro-L-arginine methyl ester hydrochloride (L-NAME) (Sigma), U46619 (9,11-dideoxy-11␣,9␣-epoxy methanoprostaglandin F2␣) (Sigma) and Lphenylephrine hydrochloride (Sigma) were dissolved in distilled water. Glibenclamide (Hoechst) was dissolved in 66.7 % DMSO.
DATA ANALYSIS
A log concentration-response curve was fitted to the data of individual experiments using GraphPad software (GraphPad, Institute for Scientific Information, San Diego, CA, USA). This computer program allows calculation of the EC50 by non-linear regression analysis, which is the concentration of the compound required to achieve the half maximal relaxant effect, based on the equation: E :
, where E : the response obtained with a given concentration A; the exponent P describes the slope of the relationship (Hill coefficient); and Emax : the maximally obtainable effect.
All data are presented as mean (SEM). Differences between means were compared using a two-tailed Student's t test for unpaired data or analysis of variance where appropriate (Graphpad Instat). P : 0.05 was considered significant.
Results
The resistance arteries dissected from the mammary tissues and used to evaluate the effects of the PDE III inhibitors (n : 116) had an average diameter of 415 (20) m and a length of 1.8 (0.03) mm. There were no significant differences in main vessel characteristics between the groups (table 1).
All arteries showed spontaneous rhythmic activity under the experimental conditions. The preparations remained stable and fully responsive to methacholine for at least 1 week after preparation when stored in the UW solution. Compared with potassium and phenylephrine, U46619 proved to be the most potent vasoconstrictor Figure 1 Chemical structures of the various compounds studied.
Table 1
Characteristics of the human vessels used in this study (mean (SEM)). L-NAME : N G -nitro-L-arginine methyl ester in all experiments. The contractile response to U46619 was not influenced by the administration of L-NAME or glibenclamide. The basal values of the U46619-induced response were comparable in all preparations ( ) and a lower degree of maximal relaxation (57.8 %) was achieved. Dipyridamole Figure 3 Log concentration-response curve for amrinone in the absence (control (n : 6) ( )) or presence of L-NAME (n : 5) ( ) or glibenclamide (n : 6) ).
concentrations ranged from 10 98 to 10 94 mol litre 91 , resulting in 83 % maximum relaxation of the basal value.
Neither L-NAME nor glibenclamide influenced the basal value of the contractile response to U46619 when administered simultaneously with the PDE inhibitors. In addition, neither L-NAME nor glibenclamide influenced the relaxant responses to amrinone, enoximone, theophylline or dipyridamole (table 4 and figs 3-6 ). However, in the presence of L-NAME a significant (P : 0.05) rightward shift was observed in the relaxation curve of milrinone. Accordingly, the pEC50 values of milrinone were also influenced by L-NAME: 2.77 (0.24) mol litre 91 with L-NAME compared with 3.49 (0.17) mol litre 91 without L-NAME (P : 0.05) ( fig. 7 ).
Discussion
Using animal models, several investigators have demonstrated that the PDE III inhibitors amrinone, milrinone and enoximone induce vasodilatation as a result of inhibition of cGMP-inhibited (cGI) PDE, thus leading to increased intracellular levels of cAMP [11] [12] [13] [14] . The effects of theophylline and dipyridamole on vascular smooth muscle are more complex.
The mode of action of theophylline involves Figure 5 Log concentration-response curve for theophylline in the absence (control (n : 5) (I)) or presence of L-NAME (n : 5) ( ) or glibenclamide (n : 8) (G).
Figure 4
Log concentration-response curve for enoximone in the absence (control (n : 6) (I)) or presence of L-NAME (n : 5) ( ) or glibenclamide (n : 6) (G).
Figure 6
Log concentration-response curve for dipyridamole in the absence (control (n : 5) (I)) or presence of L-NAME (n : 5) ( ) or glibenclamide (n : 5) (G).
Figure 7
Log concentration-response curve for milrinone in the absence (control (n : 7) (I)) or presence of L-NAME (n : 5) ( ) or glibenclamide (n : 6) (G). In the presence of L-NAME, a significant (P : 0.05) rightward shift of the relaxation curve was observed.
both non-specific phosphodiesterase inhibition and adenosine receptor antagonism [24] . In addition, unknown cellular mechanisms appear to play an additional role [25] . Dipyridamole is not only a PDE inhibitor, but also modulates adenosine metabolism, as it inhibits the cellular uptake of adenosine [26, 27] . In the present study, all agents caused concentration-dependent vasodilatation. The concentrations required were rather high compared with the results reported in the literature. However, these data may not be comparable with our results as various types of tissues were used in these studies and were obtained from different species. The use of human vessel preparations provides an obvious advantage when studying the action of agents with an influence on PDE activity, as the distribution of PDE isoenzymes is known to differ considerably between species [28] . Only Lindgren and colleagues used human vessels in their studies, but these tissues were obtained either post mortem or from patients undergoing laparotomy for various abdominal disorders, and not from healthy patients as in our study [11, 29] . Interestingly, these authors showed the importance of the mode of produced contraction on both the magnitude of the relaxant effect and the potency of PDE inhibitors on human vessels in vitro. ) as opposed to receptor-mediated (U46619) vasoconstriction [30] . The response to the PDE inhibitors in the present study may, therefore, be related partially to the method by which vasoconstriction was induced. Other important factors which may influence the efficacy of PDE inhibitors are the characteristics of the vascular beds from which the human vessels are taken. Marked variations in vascular responsiveness of isolated human coronary, renal and lung arteries have been demonstrated by Lindgren and Andersson [29] . In potassium (30 , respectively). This reduced efficacy in both lung arteries in the aforementioned investigation and mammary arteries in our study may indicate low cGI-PDE activities in these particular tissues.
Although not all vessels were used immediately after dissection, but stored in UW organ preservation fluid, there were no differences between the vessel characteristics, including maximal force development and function of endothelium (response to methacholine), between vessels of several minutes to several days old. Therefore, it is unlikely that this preservation technique was responsible for these findings. Thus far there are no reports in the literature that document the preservation of isolated vessel preparations in UW solution. Successful preservation in UW fluid for 72 h, however, has been demonstrated for entire organs taken from animals [31, 32] .
In our study, only the vasodilator effects of milrinone were partially endothelium-dependent. The addition of L-NAME 100 mol litre 91 resulted in a significant (P : 0.05) increase in the pEC50 value of milrinone compared with controls: 2.77 (0.24) vs 3.49 (0.17) mol litre
91
, respectively. So far we cannot explain why the vasodilator profile of milrinone was distinctly different from that of its structurally related analogue, amrinone. Harris and colleagues also described differential relaxant effects of milrinone and amrinone in canine arteries [30] . In their study milrinone proved a more potent vasodilator against receptor-mediated (U46619) as opposed to K ; -induced depolarizations, whereas amrinone appeared equipotent in these conditions. The reason for these different effects could not be elucidated.
Limited data are available in the literature on the interaction between the currently used PDE inhibitors and endothelium. Amrinone was reported to cause vasodilatation by both endothelium-dependent and -independent mechanisms in small pulmonary arteries of rabbits [16] . The vasodilator effects of enoximone in isolated porcine pulmonary arteries were endothelium-independent and unchanged by the addition of L-NAME 10 94 mol litre 91 [33] . Finally, Kauffman and colleagues demonstrated that the vasodilator effects of milrinone in concentrations ranging from 10 97 to 10 95 mol litre 91 occurred predominantly independent of the presence of an intact endothelium in aortic strips from rats [14] . In addition, these authors demonstrated that a high concentration of milrinone (10 94 mol litre 91 ) resulted in increased concentrations of the second messenger cGMP next to enhanced levels of the intracellular mediator cAMP. Furthermore, in the presence of methylene blue, the dose-response curve for milrinone was shifted to the right. Methylene blue acts as an inhibitor of soluble guanyl cyclase and also nitric oxide synthase [34] . Clearly the mechanism by which PDE inhibitors induce vasodilatation is complex, as recent evidence has been obtained demonstrating that cross-interactions between cAMP and cGMP occur at different levels [35, 36] .
At high concentrations milrinone acts on PDE IV and PDE V, next to PDE III inhibition [36] , PDE IV hydrolyses cAMP, whereas PDE V acts as a specific cGMP hydrolyser. It has been demonstrated that vasodilatation induced by selective PDE IV inhibitors were abolished by both L-NAME and methylene blue, indicating that the effect of PDE IV inhibitors is dependent on nitric oxide production and subsequent activation of soluble guanylate cyclase [36] . Thus, the aforementioned results combined with our data may indicate that milrinone acts as a PDE III inhibitor, independent of endothelial function, at low concentrations, whereas at higher concentrations (910 95 mol litre
) the inhibitory activity of milrinone on PDE IV, which can be partially abolished by L-NAME becomes more prominent.
The interaction of glibenclamide with milrinone was reported by Fujimoto [37] . In his experiments, inhibition of milrinone-induced vasodilatation by glibenclamide in vascular preparations of rats and guineapigs, was demonstrable only at glibenclamide concentrations as high as 10-30 mol litre 91 [37] . However, at these high concentrations glibenclamide may not act as a specific KATP channel blocker [38] . In the present investigation glibenclamide 1 mol litre 91 did not influence the vasodilator effect of any of the PDE inhibitors studied, indicating that KATP channels are not involved in the process of vasodilatation caused by these agents.
In conclusion, L-NAME sensitive nitric oxide release may contribute to the vasodilator properties of milrinone, but not to those of any of the other PDE inhibitors studied. Vasodilatation caused by PDE inhibitors does not appear to involve KATP channels.
